Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

Phase 4

Completed

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: glargine + exenatide; Drug: aspart 30

• Registration Number: NCT02467920
• Lead Sponsor: Huazhong University of Science and Technology

Brief Summary

Efficacy and Safety of Basal Insulin Glargine Combination with Exenatide bid vs Switching Premix Human Insulin to Aspart30 in T2DM with Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel trial.

Detailed Description

This is a multicentre, open-label, randomized and parallel trial that will compare the efficacy and safety of basal insulin glargine combination with Exenatide bid vs. switching premix human insulin to aspart30 in type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin. Approximately 248 patients will be enrolled in the study from China and randomized in a 1:1 ratio to one of the 2 treatment arms: once-daily insulin glargine + twice-daily exenatide + metformin; or twice-daily aspart 30 + metformin.

Study treatment will continue for 24 weeks. The primary efficacy measure is the change in HbA1c at 24 weeks. The study consists of 3 periods: a 1-week screening (period A), a 12-week run-in period (period B) and a 24-week treatment period (period C).

Study Timeline

• Study First Submitted: 2015-06-02
• Study First Submitted QC: 2015-06-05
• Study First Posted: 2015-06-10
• Study Start: 2015-08
• Primary Completion: 2017-12
• Study Completion: 2017-12
• Status Verified: 2018-11
• Last Update Submitted: 2018-11-12
• Last Update Posted: 2018-11-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 349

Inclusion Criteria

• Provision of informed consent
• Type 2 diabetic patients receiving twice-daily premixed human insulin 30 therapy ≥ 30 U/d and metformin with maximum tolerated dosage (≤ 1500mg/d)
• HbA1c > 8.0 % and < 11.0 % (HbA1c > 7.0 % and < 10.0% at randomization)
• Men and women (non-pregnant and using a medically approved birth-control method) aged ≥ 18 and ≤ 70 years
• BMI ≥ 23 and ≤ 35 kg/m2

Exclusion Criteria

• Type 1 diabetes or other specific types of diabetes
• Pregnancy, preparation for pregnancy, lactation and women of child-bearing age incapable of effective contraception methods
• Uncooperative subject because of various reasons
• Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) > twice the upper limits of normal
• Impairment of renal function, serum creatinine: ≥ 133mmol/L for female，≥ 135mmol/L for male
• Serious chronic gastrointestinal diseases
• Edema
• Serious heart diseases, such as cardiac insufficiency (level III or more according to NYHA), acute coronary syndrome and old myocardial infraction
• Blood pressure: Systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood pressure (DBP) ≥ 110mmHg
• White blood count (WBC) < 4.0×109/L or platelet count (PLT) < 90×109/L，or definite anemia (Hb：< 120g/L for male, < 110g/L for female), or other hematological diseases
• Endocrine system diseases, such as hyperthyroidism and hypercortisolism
• Experimental drug allergy or frequent hypoglycemia
• Psychiatric disorders, drug or other substance abuse
• Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy
• Stressful situations such as surgery, serious trauma and so on
• Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease
• Combined use of drugs effecting glucose metabolism such as glucocorticoid
• Tumor, especially bladder tumor and/or family history of bladder tumor and/or long-term hematuria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
glargine + exenatide	glargine + exenatide	Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
aspart 30	aspart 30	Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).

Primary Outcome Measures

Name	Time	Method
the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.	from baseline to 24-week endpoint

Secondary Outcome Measures

Name	Time	Method
Fasting blood glucose	12 weeks and 24 weeks
Change in HbA1c from baseline to 12 weeks endpoint	from baseline to 12 weeks endpoint
The percentage of participants who achieved HbA1c ≤ 6.5% and < 7%	12 weeks and 24 weeks
Daily insulin use	baseline, 12 weeks and 24 weeks
Change in body weight	from baseline to 12 and 24 weeks
The incidence and rate of hypoglycaemic events during the study	baseline, 12 weeks and 24 weeks

Trial Locations

Locations (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology; 🇨🇳 Wuhan, Hubei, China